Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free SLS Stock Alerts

SELLAS Life Sciences Group (SLS) Competitors

SELLAS Life Sciences Group logo
$11.74 +0.41 (+3.62%)
Closing price 04:00 PM Eastern
Extended Trading
$11.76 +0.02 (+0.13%)
As of 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

SLS vs. KYMR, ARWR, PTGX, IBRX, and TGTX

Should you buy SELLAS Life Sciences Group stock or one of its competitors? SELLAS Life Sciences Group's main competitors and comparable companies include Kymera Therapeutics (KYMR), Arrowhead Pharmaceuticals (ARWR), Protagonist Therapeutics (PTGX), ImmunityBio (IBRX), and TG Therapeutics (TGTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SELLAS Life Sciences Group compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and SELLAS Life Sciences Group (NASDAQ:SLS) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

SELLAS Life Sciences Group has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat SELLAS Life Sciences Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Kymera Therapeutics-285.33% -21.22% -19.21%
SELLAS Life Sciences Group N/A -35.91%-33.34%

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

SELLAS Life Sciences Group has lower revenue, but higher earnings than Kymera Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera Therapeutics$39.21M233.03-$311.35M-$3.24N/A
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.21N/A

In the previous week, SELLAS Life Sciences Group had 6 more articles in the media than Kymera Therapeutics. MarketBeat recorded 10 mentions for SELLAS Life Sciences Group and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.34 beat SELLAS Life Sciences Group's score of 0.21 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kymera Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
SELLAS Life Sciences Group
0 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Kymera Therapeutics presently has a consensus price target of $133.21, indicating a potential upside of 21.22%. SELLAS Life Sciences Group has a consensus price target of $10.00, indicating a potential downside of 15.82%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Kymera Therapeutics is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.88
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Kymera Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.56, indicating that its stock price is 156% more volatile than the broader market.

Summary

Kymera Therapeutics beats SELLAS Life Sciences Group on 10 of the 16 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Arrowhead Pharmaceuticals?

SELLAS Life Sciences Group (NASDAQ:SLS) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

SELLAS Life Sciences Group presently has a consensus target price of $10.00, indicating a potential downside of 15.82%. Arrowhead Pharmaceuticals has a consensus target price of $98.31, indicating a potential upside of 51.53%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Arrowhead Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.64

In the previous week, SELLAS Life Sciences Group had 4 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 10 mentions for SELLAS Life Sciences Group and 6 mentions for Arrowhead Pharmaceuticals. SELLAS Life Sciences Group's average media sentiment score of 0.21 beat Arrowhead Pharmaceuticals' score of 0.17 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SELLAS Life Sciences Group
0 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arrowhead Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

SELLAS Life Sciences Group has a beta of 2.56, suggesting that its share price is 156% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

Arrowhead Pharmaceuticals has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.21N/A
Arrowhead Pharmaceuticals$829.45M11.02-$1.63M-$2.25N/A

SELLAS Life Sciences Group has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. SELLAS Life Sciences Group's return on equity of -35.91% beat Arrowhead Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -35.91% -33.34%
Arrowhead Pharmaceuticals -47.79%-60.06%-17.37%

Summary

Arrowhead Pharmaceuticals beats SELLAS Life Sciences Group on 9 of the 15 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and SELLAS Life Sciences Group (NASDAQ:SLS) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Protagonist Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.56, meaning that its stock price is 156% more volatile than the broader market.

Protagonist Therapeutics has a net margin of 29.40% compared to SELLAS Life Sciences Group's net margin of 0.00%. Protagonist Therapeutics' return on equity of 12.03% beat SELLAS Life Sciences Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Protagonist Therapeutics29.40% 12.03% 11.23%
SELLAS Life Sciences Group N/A -35.91%-33.34%

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Protagonist Therapeutics presently has a consensus price target of $147.13, suggesting a potential upside of 5.00%. SELLAS Life Sciences Group has a consensus price target of $10.00, suggesting a potential downside of 15.82%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Protagonist Therapeutics is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagonist Therapeutics
0 Sell rating(s)
2 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.89
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

SELLAS Life Sciences Group has lower revenue, but higher earnings than Protagonist Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$46.02M197.04-$130.15M$1.03136.05
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.21N/A

In the previous week, SELLAS Life Sciences Group had 8 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 10 mentions for SELLAS Life Sciences Group and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat SELLAS Life Sciences Group's score of 0.21 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protagonist Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
SELLAS Life Sciences Group
0 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Protagonist Therapeutics beats SELLAS Life Sciences Group on 12 of the 15 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to ImmunityBio?

SELLAS Life Sciences Group (NASDAQ:SLS) and ImmunityBio (NASDAQ:IBRX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

SELLAS Life Sciences Group has a beta of 2.56, meaning that its share price is 156% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

SELLAS Life Sciences Group currently has a consensus target price of $10.00, suggesting a potential downside of 15.82%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 35.82%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
ImmunityBio
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than ImmunityBio. MarketBeat recorded 10 mentions for SELLAS Life Sciences Group and 9 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.67 beat SELLAS Life Sciences Group's score of 0.21 indicating that ImmunityBio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SELLAS Life Sciences Group
0 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
ImmunityBio
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

SELLAS Life Sciences Group has higher earnings, but lower revenue than ImmunityBio. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.21N/A
ImmunityBio$113.29M97.81-$351.40M-$0.97N/A

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 66.1% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

SELLAS Life Sciences Group has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -35.91% -33.34%
ImmunityBio -598.55%N/A -51.65%

Summary

ImmunityBio beats SELLAS Life Sciences Group on 9 of the 16 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to TG Therapeutics?

SELLAS Life Sciences Group (NASDAQ:SLS) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

TG Therapeutics has a net margin of 55.22% compared to SELLAS Life Sciences Group's net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat SELLAS Life Sciences Group's return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -35.91% -33.34%
TG Therapeutics 55.22%73.49%34.14%

TG Therapeutics has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.21N/A
TG Therapeutics$616.29M13.32$447.18M$2.7419.57

In the previous week, SELLAS Life Sciences Group had 6 more articles in the media than TG Therapeutics. MarketBeat recorded 10 mentions for SELLAS Life Sciences Group and 4 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.26 beat SELLAS Life Sciences Group's score of 0.21 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SELLAS Life Sciences Group
0 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
TG Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

SELLAS Life Sciences Group presently has a consensus target price of $10.00, indicating a potential downside of 15.82%. TG Therapeutics has a consensus target price of $63.00, indicating a potential upside of 17.47%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TG Therapeutics is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
TG Therapeutics
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

SELLAS Life Sciences Group has a beta of 2.56, suggesting that its share price is 156% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

Summary

TG Therapeutics beats SELLAS Life Sciences Group on 13 of the 15 factors compared between the two stocks.

Get SELLAS Life Sciences Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLS vs. The Competition

Export
MetricSELLAS Life Sciences GroupBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.37B$3.84B$7.10B$13.24B
Dividend YieldN/A3.64%2.53%15.88%
P/E Ratio-55.9012.99274.6126.05
Price / SalesN/A1,288.54601.0289.39
Price / CashN/A121.7677.3851.25
Price / Book25.5216.6310.926.31
Net Income-$26.86M-$22.67M$3.50B$361.43M
7 Day Performance1.12%-3.06%-2.11%-1.67%
1 Month Performance-17.09%-10.76%-6.34%-3.94%
1 Year Performance586.55%21.10%8.81%2.77%

SELLAS Life Sciences Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLS
SELLAS Life Sciences Group
0.4012 of 5 stars		$11.74
+3.6%		$10.00
-14.8%		+570.4%$2.37BN/AN/A13
KYMR
Kymera Therapeutics
2.1363 of 5 stars		$112.00
+0.0%		$133.21
+18.9%		+101.5%$9.31B$39.21MN/A273
ARWR
Arrowhead Pharmaceuticals
2.9419 of 5 stars		$65.46
-0.7%		$98.31
+50.2%		+85.1%$9.29B$829.45MN/A711
PTGX
Protagonist Therapeutics
1.6418 of 5 stars		$142.44
+0.4%		$147.13
+3.3%		+117.5%$9.18B$46.02M138.29141
IBRX
ImmunityBio
2.8331 of 5 stars		$8.51
+0.8%		$14.20
+66.9%		+274.2%$8.95B$113.29MN/A691

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SLS) was last updated on 10/2/2026 by MarketBeat.com Staff.
From Our Partners
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...
Paradigm Press | Sponsoredtc pixel
How Elon’s Empire Ends (and how to profit)
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...
Chaikin Analytics | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Major Buy Alert Issued for October 31st
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
They're not buying gold. They're buying this.
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel